Allogeneic Blood Requirement Perioperatively in Epoetin Beta and Placebo Patients Stratified by Total Blood Loss, Age, and Baseline Hct Level
| Explanatory Variable . | Treatment Group . | No. of Patients Included . | No. (%) of Transfused Patients . | Odds Ratio (95% CI)4-150 . |
|---|---|---|---|---|
| Total blood loss | ||||
| >750 mL | Placebo | 17 | 14 (82.2) | 0.05 |
| Epoetin beta | 21 | 4 (19.1) | (0.01-0.32) | |
| ≤750 mL | Placebo | 19 | 5 (26.3) | 0.0 |
| Epoetin beta | 15 | 0 (0.0) | (0.00-0.92) | |
| Age | ||||
| ≥60 yr | Placebo | 18 | 14 (77.8) | 0.03 |
| Epoetin beta | 11 | 1 (9.1) | (0.00-0.35) | |
| <60 yr | Placebo | 18 | 5 (27.8) | 0.35 |
| Epoetin beta | 25 | 3 (12.0) | (0.05-2.23) | |
| Hct at baseline | ||||
| ≥0.42 | Placebo | 17 | 5 (29.4) | 0.21 |
| Epoetin beta | 25 | 2 (8.0) | (0.02-1.57) | |
| <0.42 | Placebo | 19 | 14 (73.7) | 0.08 |
| Epoetin beta | 11 | 2 (18.2) | (0.01-0.62) |
| Explanatory Variable . | Treatment Group . | No. of Patients Included . | No. (%) of Transfused Patients . | Odds Ratio (95% CI)4-150 . |
|---|---|---|---|---|
| Total blood loss | ||||
| >750 mL | Placebo | 17 | 14 (82.2) | 0.05 |
| Epoetin beta | 21 | 4 (19.1) | (0.01-0.32) | |
| ≤750 mL | Placebo | 19 | 5 (26.3) | 0.0 |
| Epoetin beta | 15 | 0 (0.0) | (0.00-0.92) | |
| Age | ||||
| ≥60 yr | Placebo | 18 | 14 (77.8) | 0.03 |
| Epoetin beta | 11 | 1 (9.1) | (0.00-0.35) | |
| <60 yr | Placebo | 18 | 5 (27.8) | 0.35 |
| Epoetin beta | 25 | 3 (12.0) | (0.05-2.23) | |
| Hct at baseline | ||||
| ≥0.42 | Placebo | 17 | 5 (29.4) | 0.21 |
| Epoetin beta | 25 | 2 (8.0) | (0.02-1.57) | |
| <0.42 | Placebo | 19 | 14 (73.7) | 0.08 |
| Epoetin beta | 11 | 2 (18.2) | (0.01-0.62) |
An odds ratio <1 indicates a reduced risk for blood transfusions in patients treated with epoetin beta compared with placebo.